Kerry L. Fillgrove

Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention

Stephanie E. Barrett, Ryan S. Teller, Seth Forster et al. · Antimicrobial Agents and Chemotherapy · 2018 · 133 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Triclosan inhibits enoyl-reductase of type I fatty acid synthase in vitro and is cytotoxic to MCF-7 and SKBr-3 breast cancer cells

Binqiu Liu, Yingqiang Wang, Kerry L. Fillgrove et al. · Cancer Chemotherapy and Pharmacology · 2002 · 129 citations

Medicine, Oncology, Pharmacology +13

High‐throughput, accurate mass liquid chromatography/tandem mass spectrometry on a quadrupole time‐of‐flight system as a ‘first‐line’ approach for metabolite identification studies

Philip R. Tiller, Sean Yu, José Castro‐Perez et al. · Rapid Communications in Mass Spectrometry · 2008 · 112 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12

Mechanistic Diversity of Fosfomycin Resistance in Pathogenic Microorganisms

Kerry L. Fillgrove, Svetlana Pakhomova, Marcia E. Newcomer et al. · Journal of the American Chemical Society · 2003 · 97 citations

Life Sciences, Biochemistry, Microbiology +16

Structure and Mechanism of the Genomically Encoded Fosfomycin Resistance Protein, FosX, from <i>Listeria monocytogenes</i>^,

Kerry L. Fillgrove, Svetlana Pakhomova, Matthew R. Schaab et al. · Biochemistry · 2007 · 93 citations

Life Sciences, Microbiology, Molecular Biology +10